Catalyst Pharmaceuticals, Inc. (CPRX) — Fair Value Analysis

Base-case fair value (P50): $35.10 · Current price: $31.41 · Verdict: Fairly Valued

The Verdict on CPRX

Based on our proprietary Monte Carlo simulations, CATALYST PHARMACEUTICALS INC (CPRX) is currently deemed Fairly Valued. With a current price of $31.41, our median fair value (P50) stands at $35.10, suggesting an +11.7% upside potential from its present market price. This assessment incorporates thousands of forward-looking scenarios, rigorously analyzing CPRX's fundamental drivers to establish a robust valuation range. While the current market price of $31.41 sits below our median target, the implied +11.7% is consistent with an equity trading within its intrinsic value band, reflecting a balanced risk-reward profile rather than deep undervaluation. The extensive Monte Carlo analysis underpins this "Fairly Valued" verdict, providing a comprehensive view beyond simple point estimates.

How CPRX stacks up against peers

Despite its sector being unclassified (n/a), CPRX demonstrates a strong quality tier in terms of operational and financial health relative to other companies we cover. This robust fundamental standing is a pivotal factor in its valuation, setting it apart from peers that may exhibit weaker underlying metrics or greater financial volatility. The $35.10 fair value directly reflects this strength and resilience. While direct sector comparisons are challenging given the 'n/a' classification, the consistent strong quality tier signals efficient management and a solid operational foundation, contributing significantly to the +11.7% potential identified through our models at the current $31.41. This tier provides a critical lens for understanding CPRX's relative position.

What this means for investors

For investors considering CATALYST PHARMACEUTICALS INC, the "Fairly Valued" verdict, coupled with a strong quality tier and an +11.7% upside to our $35.10 fair value, suggests that the market is largely reflecting CPRX's intrinsic value at $31.41. While a modest upside remains towards our $35.10, investors should recognize that the stock is not deeply undervalued based on our simulations. Both potential downside and upside scenarios, as explored in our extensive Monte Carlo analysis, are comprehensively factored into this assessment. To gain a complete understanding of the full bear and bull case distribution and to track CPRX's fair value as new fundamentals are released, sign up for a free FairCurve account today.